Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma ...
Bio-Rad posts robust margins and liquidity, while Charles River leads in global drug discovery services. Explore how their fundamentals stack up for investors.
The recent entry of an activist investor draws attention to the potential for Bio-Rad's shares to be re-rated. Read more on ...
PLEASANTON — Bio-Rad Laboratories, setting the stage for a big expansion in the East Bay, has bought a two-building complex in Pleasanton’s Hacienda Business Park to accommodate plans for more workers ...
Within the last quarter, Bio-Rad Laboratories (NYSE:BIO) has observed the following analyst ratings: These 4 analysts have an average price target of $546.5 versus the current price of Bio-Rad ...
(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...
BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its Real-Time qPCR ...
Oct 26 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro ...
PLEASANTON — Bio-Rad Laboratories, setting the stage for a big expansion in the East Bay, has bought a two-building complex in Pleasanton’s Hacienda Business Park to accommodate plans for more workers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results